Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfasalazine for Liver Fibrosis/Cirrhosis
NCT06293378Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Feb 2024
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of 5-aminosalicylic acid + sulphasalazine in Liver Fibrosis (LF) and Liver cirrhosis (LC) (11 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Hepatic fibrosis at 13 months, Serum alkaline phosphatase at 13 months and 5 more. Started Feb 2024; status: recruiting.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
Liver Fibrosis (LF)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT06293378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293378.